China · Series C startup

Who invested in Hinova Pharma

2 rounds we have observed, with the 3 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcare

Funding summaryUpdated 26 Oct 2026

$187Mraised across 2 rounds since 2019, from 2 sources

$40MSeries B$147MSeries C
Latest round
Series C, $147MOct 2020
Step-upi
3.7×
Investors
3
See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

2020
$40MSeries B$147MSeries C
First round
Series B, $40M
Jul 2019
Biggest round
$147M
Series C · Oct 2020
Between rounds
14 months
from the last two

The rounds

  1. Oct 2020
    Series C$147M1 new

    Source recorded

  2. Jul 2019
    Series B$40M2 new

    Reported by Voice

Who was in which round

The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.

Everyone who backed them

Hermed CapitalVC firm1round
Fosun CapitalCompany1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Hinova Pharma

Who invested in Hinova Pharma?

Hinova Pharma's investors include GF Xinde Investment Management, Hermed Capital and Fosun Capital.

How much has Hinova Pharma raised?

Hinova Pharma has raised $187M across 2 rounds since 2019.

When did Hinova Pharma last raise?

Hinova Pharma's most recent round was a Series C of $147M in Oct 2020.

What was Hinova Pharma's biggest round?

Its most recent round, $147M in Oct 2020, is also its largest on record.

Who backed Hinova Pharma first?

Hinova Pharma's first round on record, in Jul 2019, was backed by Hermed Capital and Fosun Capital.

What stage is Hinova Pharma at?

Hinova Pharma's latest named round is a Series C, in Oct 2020.

Where is Hinova Pharma based?

Hinova Pharma is based in China.

Companies like Hinova Pharma

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.